Skip to content

G&A at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$101.25M+189%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$11.03M-41.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$28.24M+137%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$62.59M+302%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$50.83M+43.1%
Moderna logo
ModernaMRNA
$173M-18.4%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%
Enterprise value$4.25B+1,265%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s G&A?
Erasca, Inc. (ERAS) reported G&A of $10.65M in Q1 2026.
How has Erasca, Inc.'s G&A changed year-over-year?
Erasca, Inc.'s G&A increased by 10.2% year-over-year, from $9.66M to $10.65M.
What is the long-term trend for Erasca, Inc.'s G&A?
Over 4 years (2021 to 2025), Erasca, Inc.'s G&A has grown at a 14.3% compound annual growth rate (CAGR), from $22.62M to $38.55M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.